Sustained Drug Delivery

This development is expected to provide valuable data on Vivani's NanoPortal implants under development, including NPM‑139, which could address a growing segment of patients who would prefer a convenient once‑ or twice‑yearly treatment option. The agreement with Novo Nordisk also underscores Vivani's proprietary NanoPortal technology and its potential for delivering drug molecules steadily over extended periods of time.